These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

822 related items for PubMed ID: 26272602

  • 1. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y, Kimachi K, Okada Y, Matsuura K, Ooyama Y, Ibaragi K, Kino Y, Ueda K.
    Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.
    Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.
    BMC Infect Dis; 2013 Jul 24; 13():343. PubMed ID: 23883186
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
    Choi WS, Noh JY, Song JY, Cheong HJ, Wie SH, Lee JS, Lee J, Kim SW, Jeong HW, Jung SI, Kim YS, Woo HJ, Kim KH, Kim H, Kim WJ.
    Hum Vaccin Immunother; 2017 Jul 03; 13(7):1653-1660. PubMed ID: 28406746
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.
    Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, Aranza Doniz C, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain VK.
    Vaccine; 2014 Mar 14; 32(13):1480-7. PubMed ID: 24486352
    [Abstract] [Full Text] [Related]

  • 5. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M.
    Vaccine; 2013 Nov 12; 31(47):5572-8. PubMed ID: 24016810
    [Abstract] [Full Text] [Related]

  • 6. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
    Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD.
    Vaccine; 2013 Jan 21; 31(5):770-6. PubMed ID: 23228813
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults.
    Song JY, Lee J, Woo HJ, Wie SH, Lee JS, Kim SW, Kim TH, Jung SI, Noh JY, Choi WS, Cheong HJ, Kim WJ.
    Hum Vaccin Immunother; 2019 Jan 21; 15(3):710-716. PubMed ID: 30396317
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
    Rodriguez Weber MA, Claeys C, Aranza Doniz C, Feng Y, Innis BL, Jain VK, Peeters M.
    Pediatr Infect Dis J; 2014 Dec 21; 33(12):1262-9. PubMed ID: 25386965
    [Abstract] [Full Text] [Related]

  • 9. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
    van de Witte S, Nauta J, Montomoli E, Weckx J.
    Vaccine; 2018 Sep 25; 36(40):6030-6038. PubMed ID: 29709447
    [Abstract] [Full Text] [Related]

  • 10. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.
    Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.
    J Infect Dis; 2013 Jun 15; 207(12):1878-87. PubMed ID: 23470848
    [Abstract] [Full Text] [Related]

  • 11. Randomized, single-blind, active-controlled phase I clinical trial to evaluate the immunogenicity and safety of GC3114 (high-dose, quadrivalent influenza vaccine) in healthy adults.
    Noh JY, Jang YS, Lee SN, Choi MJ, Yoon JG, Yu DH, Song JY, Cheong HJ, Kim WJ.
    Vaccine; 2019 Aug 23; 37(36):5171-5176. PubMed ID: 31377075
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in healthy subjects aged 3 to 17 years old: A phase III, open label, single-arm study.
    Chang CY, Cho CY, Lai CC, Lu CY, Chang LY, Hung MC, Huang LM, Wu KG.
    Vaccine; 2020 May 08; 38(22):3839-3846. PubMed ID: 32284272
    [Abstract] [Full Text] [Related]

  • 13. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China.
    Wang SY, Liu SZ, Chu K, Zhao Y, Zhu FC, Hu YM, Meng FY, Li JX, Luo L, Yang JY, Liu P, Yu J.
    Expert Rev Vaccines; 2017 Nov 08; 16(11):1155-1169. PubMed ID: 28870140
    [Abstract] [Full Text] [Related]

  • 14. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season.
    Ganczak M, Dubiel P, Drozd-Dąbrowska M, Hallmann-Szelińska E, Szymański K, Brydak LB.
    Int J Environ Res Public Health; 2019 Nov 14; 16(22):. PubMed ID: 31739554
    [Abstract] [Full Text] [Related]

  • 15. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, Santos J, Montalban MC, de Looze FJ, Eizenberg P, Hall S, Dupuy M, Hutagalung Y, Pépin S, Saville M.
    Vaccine; 2015 May 15; 33(21):2485-92. PubMed ID: 25843270
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.
    Vinnemeier CD, Fischer-Herr J, Meyer S, Liebig K, Theeß W, Burchard GD, Cramer JP.
    Hum Vaccin Immunother; 2014 May 15; 10(2):441-8. PubMed ID: 24240428
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity and safety of Quadrivalent Influenza HA vaccine in Indonesian children: An open-labeled, bridging, clinical study.
    Dhamayanti M, Tarigan R, Fadlyana E, Prasetyo D, Amalia N, Rusmil VK, Sari RM, Bachtiar NS, Rusmil K, Kartasasmita CB.
    Vaccine; 2020 Jan 29; 38(5):993-1000. PubMed ID: 31862195
    [Abstract] [Full Text] [Related]

  • 18. Safety and Immunogenicity of an Egg-Cultivated Quadrivalent Inactivated Split-virion Influenza Vaccine (GC3110A) in Healthy Korean Children: a Randomized, Double-blinded, Active-controlled Phase III Study.
    Lee J, Lee KY, Kim JH, Kim CS, Eun BW, Kim HM, Kim DH, Hong YJ, Choi YY, Jo DS, Ma SH, Kang JH.
    J Korean Med Sci; 2018 Mar 26; 33(13):e100. PubMed ID: 29573247
    [Abstract] [Full Text] [Related]

  • 19. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults.
    Block SL, Yi T, Sheldon E, Dubovsky F, Falloon J.
    Vaccine; 2011 Nov 21; 29(50):9391-7. PubMed ID: 21983154
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent influenza vaccine: a Phase III, open-label study of adults in Brazil.
    Zerbini CA, Ribeiro Dos Santos R, Jose Nunes M, Soni J, Li P, Jain VK, Ofori-Anyinam O.
    Braz J Infect Dis; 2017 Nov 21; 21(1):63-70. PubMed ID: 27912069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.